poisar

Stocks · News reference

PTC Therapeutics Expands Rare Disease Portfolio with 'Unique Opportunity'

Vandana Singh

PTC Therapeutics plans to acquire Sangamo’s ST-920 Fabry disease program for $111 million upfront, with FDA filing expected in Q4 2026.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

IBRNPSCHPTCT
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    Invesco Q3 Earnings Coming Up: Will AUM Growth Drive Results Higher?

    Invesco is set to report Q3 2026 earnings on Oct. 27 with projected earnings growth of 21.3% y/y and revenue growth of 17.3%. While AUM grew 2.7% sequentially to $2.54 trillion and performance fees are expected to rise significantly, higher compensation costs and $15 million in Alpha implementation expenses pose headwinds. The company has a negative Earnings ESP of -0.19% and Zacks Rank #3, suggesting low probability of beating consensus estimates.

    BKLNCGWCQQQCUTDIVG
  2. Na

    Invesco (IVZ) Earnings Expected to Grow: Should You Buy?

    Invesco is expected to report Q3 2026 earnings of $0.74 per share (up 21.3% YoY) and revenues of $1.39 billion (up 17.3% YoY) on October 27. However, recent analyst estimate revisions have turned slightly bearish, with a negative Earnings ESP of -0.19% and a Zacks Rank #3 (Hold), making it difficult to predict an earnings beat despite the company's strong historical track record of beating estimates.

    BKLNCGWCQQQCUTDIVG
  3. Na

    BlackRock (BLK) Tops Q3 Earnings and Revenue Estimates

    BlackRock reported Q3 2026 earnings of $15.93 per share, beating consensus estimates of $13.97 by 14.03%, with revenues of $7.75 billion exceeding expectations by 3.96%. However, the stock has underperformed the S&P 500 by 14% year-to-date. The company received a Zacks Rank #3 (Hold) rating, suggesting near-term performance in line with the market. The Financial - Investment Management industry ranks in the bottom 39% of sectors.

    BLKDIVBBKLNCGWCQQQ
  4. Na

    Invesco's AUM Rises in August: Will the Momentum Continue?

    Invesco's assets under management rose 4.7% in August 2026 to $2.56 trillion, driven by $49 billion in market gains and $27.6 billion in long-term net inflows. ETFs, QQQ, and liquidity products led growth, with QQQ AUM climbing 8% and liquidity AUM rising 15.6%. The company's strong first-half momentum and diversified investment platform position it well for continued asset gathering.

    BKLNCGWCQQQCUTDIVG